A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Epistemonikos ID: 1f2291401e1ac7586068ff8cb08a8b9939fb05f4
First added on: May 20, 2024